Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments.

See the whole Series here:

https://www.thelancet.com/series-do/cancer-control-in-middle-east?dgcid=buzzsprout_icw_podcast_lanonccanceremro25_lanonc

Watch the Series video here: https://youtu.be/t3AGdouXpqg

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference.

If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167

Articles discussed in this podcast episode include:

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo

#asco2025

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv